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Introduction
As cancer survival rates continue to improve, optimising 
survivorship care has become a national priority in the Repub-
lic of Ireland1–3. Exercise rehabilitation is a care strategy with 
considerable potential to optimise physical function and qual-
ity of life in cancer survivorship4. However, recruitment 
and retention in cancer exercise trials remains a challenge5, 
which may be detrimental to the validity of trial results. Accord-
ingly, there is strong rationale to investigate strategies which 
may aid recruitment and retention to cancer exercise trials.
Public and Patient Involvement (PPI) has been described as 
research being carried out with or by members of the public 
rather than to, about, or for them6,7. This approach to research 
is encouraged as it is felt that those affected by research should 
have a say in how it is carried out8. There is also evolving evi-
dence that PPI can increase the rate of recruitment to research 
and improve its quality and impact9. A recent systematic 
review and meta-analysis by Crocker et al.6 investigating the 
impact of PPI on patient enrolment and retention in clinical 
trials demonstrated that PPI significantly increased the odds of 
participant recruitment (odds ratio 1.16, 95% confidence inter-
val and prediction interval 1.01 to 1.34). An example of a PPI 
strategy to enhance trial enrolment is the inclusion of patients 
and the public in the design of participant information. Tradi-
tional participant information has consistently been criticized 
for being too lengthy, using technical or difficult language, and 
for lacking navigability and visual appeal10. Furthermore, it is 
reported that patients with cancer may gain little understanding 
of the risks and benefits of research from provided participant 
information11. Therefore, participant information may in 
fact become a barrier to trial understanding and enrolment, 
and there is therefore considerable rationale to optimise trial 
participant information. 
The Rehabilitation Strategies following Oesophago-gastric 
and Hepatopancreaticobiliary cancer (ReStOre II) trial 
(ClinicalTrials.gov Identifier: NCT03958019) will examine by 
randomised controlled trial (RCT) a multidisciplinary reha-
bilitation programme (ReStOre II) for survivors of cancer of 
the oesophagus, stomach, pancreas, and liver. The ReStOre II 
programme will consist of supervised and self-managed exercise, 
1:1 dietary counselling, and education sessions. In a previous pilot 
RCT, this programme was found to lead to significant improve-
ments in cardiorespiratory fitness12, and positively impact on 
physical, mental and social wellbeing13. Furthermore, a patient 
recruitment rate of 40% was achieved12. Whilst this rate is higher 
than rates cited by other cancer rehabilitation programmes 
(11.1%)14, given the potential benefits of participation there is 
just cause to attempt to achieve greater rates of enrolment for 
ReStOre II. Importantly, an increased recruitment rate would 
accelerate the progress, completion and dissemination of the 
ReStOre II trial. To this end, this study within a trial (SWAT) 
will engage with patients and their families and ask them to 
contribute to the development of participant information and 
examine its impact by an embedded randomised controlled trial.
Study aims
This SWAT aims to examine within the ReStOre II RCT if 
participant information co-developed by patients and their 
families can lead to improved recruitment rates, retention, 
and participant understanding of the study in comparison 
to standard participant information leaflets.
Specific objectives are:
฀•฀฀฀฀฀฀฀฀To engage with patients with upper gastrointestinal 
(UGI) or hepatopancreaticobiliary (HPB) cancer, namely 
oesophageal/gastric/pancreatic/liver cancer and their 
family members to develop participant information for 
the ReStOre II RCT.
฀•฀฀฀฀฀฀฀฀To examine the impact of the patient and family 
co-developed participant information on ReStOre II 
recruitment rates.
฀•฀฀฀฀฀฀฀฀To determine the impact of the patient and family co- 
developed participant information on ReStOre II retention 
rates.
฀•฀฀฀฀฀฀฀฀To explore the impact of the patient and family 
co-developed participant information on patients’ 
understanding of the ReStOre II trial.
Methods
Study design
The study is divided into two phases; Phase I (development) 
and Phase II (evaluation). The study design is presented in 
Figure 1. Phase I will utilise qualitative methods to develop 
and refine the patient and family co-developed participant 
information. In Phase II, the patient and family co-developed 
participant information will be compared to standard partici-
pation information by a randomised controlled trial embedded 
within the ReStOre II randomised controlled trial. 
Study participants
Phase I of the SWAT will recruit patients who have 
previously undergone surgery for cancer of the oesophagus, 
stomach, liver, or pancreas, and/or the spouses, partners or close 
relatives of these patients. Individuals with communication or 
cognitive difficulty that would impair their ability to take part 
in a semi-structured focus group/interview will be excluded. 
Twenty participants will be recruited to ensure a diverse range 
of views are obtained. Three strategies will be utilised for 
recruitment: i) previous participants of the ReStOre I trial 
will be sent a letter and participation leaflet inviting them 
and their partner/spouse/close relative to participate; ii) par-
ticipant information leaflets will be supplied to patients attend-
ing the UGI cancer clinic at St James’s Hospital (SJH); and 
iii) potential participants may make themselves known to 
the research team by replying to adverts disseminated through 
our charity partners, the Oesophageal Cancer Fund and the 
Irish Cancer Society. Individuals who are willing to partici-
pate in Phase I will be required to give written informed consent 
for participation and data processing.
Phase II of the SWAT will involve potential ReStOre II RCT 
participants. The ReStOre II RCT will recruit patients with 
cancer of the oesophagus/stomach/liver or pancreas, who have 
completed curative treatment, from three hospitals in Dublin, 
Ireland; SJH, St Vincent’s University Hospital, and Tallaght Uni-
versity Hospital (TUH). Participants must be ฀≥ three months 
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post oesophagectomy, total gastrectomy, pancreaticoduo-
denectomy, or major liver resection (+/- neoadjuvant/adjuvant 
chemotherapy/chemoradiotherapy) and any adjuvant treatment 
must be complete. Exclusion criteria includes evidence of ongo-
ing serious post-operative morbidity, evidence of active or 
recurrent disease or any contraindication to maximal exercise 
testing.
The SWAT
Phase I. Phase I of the SWAT will be carried out over two 
sub-phases: Phase Ia (development of the patient and family 
co-developed participant information) and Phase Ib (refinement 
of the patient and family co-developed participant information).
Phase Ia - Development of patient and family co-developed 
participant information. In Phase Ia, survivors of UGI and 
HPB cancer and spouses, partners, and close family members 
of these patients will be invited to participate in a focus discus-
sion group or individual interview study, as preferred. The focus 
groups and interviews will take place in the Clinical Research 
Facility at SJH. Individuals who consent to participation and 
are unable to attend SJH at the time of the focus group will be 
offered the opportunity to take part in a 1:1 interview at SJH 
or via phone or Skype. The focus group or interview will be 
led by a qualitative researcher experienced in PPI initiatives. 
The focus group discussion and interviews will be audio recorded. 
Using an agreed topic guide15, participants will be invited to dis-
cuss participant information development, by asking them to 
comment on the participant information leaflet developed for 
the ReStOre II trial and make suggestions for amending and 
enhancing it. The Consensus-Orientated-Decision-Making 
(CODM) model16 will be used to guide the group to reach a 
consensus.
The CODM model steps include:
1. Framing the topic
2. Open discussion
3. Identifying underlying concerns
4. Collaborative proposal building
5. Choosing a direction
6. Synthesizing a final proposal
7. Closure
The discussion will also focus on core aspects of informa-
tion utility and quality: content, language, structure, navigation, 
and visual impact.
Focus group/interview recordings will be transcribed verbatim. 
A basic thematic analysis will be undertaken to inform the revi-
sion of participant recruitment materials. This will be guided 
by the Braun and Clarke17 model and using an information 
quality framework of: content, language, structure, naviga-
tion, and visual impact. Researchers will then use the focus 
group/interview findings to develop an initial draft of the revised 
patient and family co-developed participant information, a 
form of ‘participatory design’18,19.
Figure 1. Study design. ReStOre, Rehabilitation Strategies Following Oesophago-gastric and Hepatopancreaticobiliary Cancer.
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Phase Ib – Refinement of the patient and family co-developed 
participant information. In Phase Ib, participants from 
Phase Ia will be invited to return to take part in a second focus 
group/interview. If insufficient participants from the Phase 
Ia data collection are available for Phase 1b, we will recruit 
new participants for Phase Ib by applying the same entry 
criteria. At this session, participants will comment on the 
participant information that has been developed following the 
feedback received in Phase Ia, focusing on its structure, content, 
language, visual impact and navigation. Similar to Phase Ia, the 
Phase Ib focus groups and interviews will be audio recorded 
and then transcribed verbatim and reported using a basic 
thematic analysis. Researchers will then act on patient and 
relative feedback to edit different sections of the participant 
information. At the end of this phase of the study, a final draft 
of the patient and family co-developed participant information 
will be approved by the research team and patient group. The 
resultant final participant information will then be submitted as 
an amendment to the research ethics application for the 
ReStOre II trial (TUH/SJH and St Vincent’s Hospital Research 
Ethics Committees).
Phase I Data management
The Data Management Plan15 will outline how research data 
will be handled during and after the project. All participants 
will be allocated a unique study code. The key to the study 
code will be stored securely and separately. All transcripts 
will be stored in locked filing cabinets, in a locked office in a 
restricted access building with swipe access. Electronic records 
will be stored on password protected encrypted devices. 
Phase II. Following ethical approval, the new patient and 
family co-developed participant information will be tested in 
a prospective, randomised, single blind, parallel trial design. 
Potential ReStOre II trial participants will be randomised to 
receive either the standard participant information (control group) 
or the patient and family co-developed participant information 
(intervention group) when initially approached for recruit-
ment. Patients will be approached for recruitment at the upper 
gastrointestinal cancer clinics at SJH, SVUH, and TUH. 
If recruitment rates are suboptimal, the study will also 
be advertised through the social media platforms of our 
charity partners, the Irish Cancer Society and the Oesophageal 
Cancer Fund.
Randomisation
The type of information leaflet each potential participant will 
be sent will be determined by random allocation. Randomi-
sation will be overseen by the Clinical Research Facility at 
SJH. Potential participants will be randomised in a 1:1 ratio. 
Block randomisation with random varying block sizes will 
be used, with the block sizes specified by the Clinical Research 
Facility and not shared with other researchers. The alloca-
tion lists will be generated by a randomisation system and 
shared and accessed only by an independent member of 
the research team not involved in recruitment, to achieve 
concealment of allocation.
Blinding
Potential participants invited to participate in ReStOre II will 
be blinded to the nature and objectives of the SWAT. The 
trial team will not be blinded to the allocation of groups.
Outcome measures
The two forms of participant information will be compared 
in terms of participant recruitment rates (primary outcome), 
defined as the proportion of participants in each intervention 
group that are randomised into ReStOre II.
The secondary outcome will be understanding of the trial, 
which will be assessed using the TRECA Decision-Making 
Questionnaire (DMQ)15. The DMQ was developed within the 
TRECA study, which is evaluating digital information about 
trials for children and adolescents. The questionnaire asks 
participants to evaluate various aspects of the information 
and its utility to inform decisions about trial participation. It 
includes nine Likert items and three open response items20. 
One week after receiving the participant information partici-
pants will receive a follow-up phone call from a member of the 
research team to confirm if they are interested/ not interested in 
participation. Following their decision to decline or accept 
participation individuals will be asked to complete the 
DMQ. The DMQ will be posted to individuals and they will 
be given a stamped addressed envelope to return it to the 
Research team. 
A further secondary outcome will be retention to the trial, 
defined as the proportion of randomised participants who par-
ticipated in the ReStOre II main trial up to and including the first 
follow-up data collection time point.
Phase II-Data Management
Electronic and paper data will be stored securely and safely 
as outlined above in Phase I. 
Sample size calculations
The sample size calculations for the ReStOre II trial have been 
outlined in the main trial protocol. As is usual with a SWAT, 
we did not undertake a formal power calculation to determine 
the sample size21, since the sample size is constrained by the 
number of patients being approached in the ReStOre II host trial. 
We anticipate a sample size of approximately 300 patients 
for the embedded SWAT, which is the number of people who 
will be approached to participate in the ReStOre II host trial 
(150 per group). Analysed independently, this sample would 
give 80% power to detect an improvement in recruitment rates 
from 40 to 56%.
Analysis plan
Statistical analysis will comprise evaluation of the impact of 
the revised information on: i) rates of recruitment to the trial 
(assessed by odds ratios); ii) questionnaire scores, analysed 
separately for recruited participants and those who refused 
ReStOre II participation; and iii) rates of retention in the 
ReStOre II trial (to the first follow-up data collection time point, 
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assessed by odds ratios). Analyses will be conducted on an 
intention to treat basis, including all randomised participants 
on the basis of the groups to which they were randomised. 
Analysis will be conducted using two-sided significance tests at 
the 5% significance level. For analysis of the primary outcome, 
logistic regression will be used to produce odds ratios and their 
associated 95% confidence intervals and p-values.
Safety
There are no anticipated harms from taking part in this SWAT. 
Any incidents/serious incidents that occur will be recorded. 
Any serious incidents will be reported to the PI and the ethics 
committee (within 24 hours).
Trial management and governance
The management of this SWAT will be overseen by the ReStOre 
II trial management groups; a Trial management Group 
(TMG), Trial Steering Committee (TSC) and an Independent 
Data Monitoring Committee (IDMC). The TMG will oversee 
the daily management of the SWAT. The TSC will meet 
biannually and provide oversight of the SWAT. The IDMC will 
also meet biannually and will monitor SWAT data to ensure 
the safety of the participants. The CRF at SJH will provide 
independent monitoring and will make reports to the IDMC.
Dissemination
The results of this SWAT will be disseminated via peer-
reviewed publications and conference presentations. Results 
will also be shared with participants and their families at 
an education symposium when the study is complete. Upon 
completion of the trial an anonymised data set will be depos-
ited on a secure online repository in line with open access 
publication requirements.
Study status
Recruitment for Phase I began in October 2019.
Ethical statement
Ethical approval for Phase I has been obtained from TUH/SJH 
Research Ethics Committee (REC: 2019-09 List 35 (08)). All 
Phase I participants will be required to give written informed 
consent. As Phase II is embedded in the multicentre ReStOre 
II RCT, ethical approval has been sought for Phase II in 
conjunction with the ReStOre II RCT ethics application from 
both TUH/SJH REC and St Vincent’s University Hospital 
REC. Any amendments to the planned protocol will be reported 
to the ethics committees.
Discussion
Optimising cancer survivorship care is a health service priority 
both nationally and internationally1,22. Given the hypothesised 
benefits of exercise in cancer survivorship4, and the typical 
poor accrual rates to cancer exercise trials5, it is imperative 
to explore strategies to optimise recruitment to such trials. 
PPI has been employed successfully to optimise recruitment 
in other clinical populations6; this protocol sets out to exam-
ine by a SWAT if patient and family co-developed participant 
information will have a beneficial impact on recruitment to 
the ReStOre II trial. If successful, this SWAT will provide 
a useful template for maximising enrolment to exercise 
rehabilitation trials and other trials in cancer survivorship.
Data availability
Underlying data
All data underlying the results are available as part of the 
article and no additional source data are required.
Extended data
Open Science Framework: Patient and family co-developed 
participant information to improve recruitment rates, reten-
tion, and patient understanding in the Rehabilitation Strategies 
Following Oesophago-gastric and Hepatopancreaticobiliary 
Cancer (ReStOre II) trial: Protocol for a study within a trial 
(SWAT). https://doi.org/10.17605/OSF.IO/KQXGH15.
This project contains the following extended data:
-    190401 ReStOre II SWAT Focus Group Interview 
Guide.pdf
-    190401 ReStOre II SWAT Phase I Consent Form.pdf
-    190530 RESTORE II SWAT Decision Making 
Questionnaire Version 1.pdf
-    190719 Data Management Plan (DMP) Version 1 RESTORE 
SWAT.pdf
Reporting guidelines
Open Science Framework: SPIRIT checklist for “Patient 
and family co-developed participant information to improve 
recruitment rates, retention, and patient understanding in the 
Rehabilitation Strategies Following Oesophago-gastric and 
Hepatopancreaticobiliary Cancer (ReStOre II) trial: Protocol for 
a study within a trial (SWAT)”. https://doi.org/10.17605/OSF.IO/
WH3YM.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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